PharmaDirections congratulates Hyperion Therapeutics on achieving an NDA approval for their RAVICTI™ (glycerol phenylbutyrate) Liquid for Treatment of Urea Cycle Disorders  PharmaDirections is proud to have helped in the development of Hyperion's first product to during their clinical development program